Scaling Scientific R&D with AI Supercomputing Infrastructure — with Thomas Fuchs of Eli Lilly

2026-05-19 · Source: The AI in Business Podcast · Field: Science & Research — Health & Medical Research, Life Sciences & Biology, Mathematics & Computational Sciences · Depth: Intermediate, extended

Summary

Eli Lilly & Company is deploying a new AI supercomputing platform, featuring the NVIDIA DGX Superpod B300 system architecture with 1,000 B300 chips, to overcome infrastructure constraints in pharmaceutical R&D. This platform, significantly more powerful than previous supercomputers (one B300 chip equals 7 million 1989 supercomputers), enables researchers to work with larger models and leverage decades of experimental data. The initiative aims to accelerate scientific discovery, improve early prediction of molecular properties, and optimize manufacturing processes, such as speeding up the drying of APIs to deliver millions of doses faster. Lilly also partners with ToonLab for collaboration and external biotech access, emphasizing AI infrastructure as a core strategic capability.

Key takeaway

For Directors of AI/ML in pharmaceutical R&D scaling AI initiatives, investing in dedicated AI supercomputing infrastructure is crucial. You should prioritize platforms like the NVIDIA DGX Superpod B300 that enable larger models, secure data environments, and the effective use of both positive and "negative" experimental data. This approach moves beyond incremental gains to transformative scientific discovery, de-risking development, and accelerating patient access to medicines.

Key insights

AI supercomputing transforms pharmaceutical R&D by enabling larger models, leveraging vast data, and accelerating scientific discovery and manufacturing.

Principles

• AI infrastructure is a core strategic capability.
• Leveraging "negative data" improves model performance.
• ROI extends beyond time/cost to scientific depth.

In practice

• Reduce unnecessary lab experiments.
• Improve early prediction of molecular properties.
• Accelerate key manufacturing steps.

Topics

• AI Supercomputing
• Pharmaceutical R&D
• Drug Discovery
• NVIDIA DGX Superpod
• Negative Data
• AI Infrastructure
• Manufacturing Optimization

Best for: CTO, VP of Engineering/Data, Executive, AI Scientist, Director of AI/ML, Research Scientist

Related on AIssential

• Now Live: The World’s Most Powerful AI Factory for Pharmaceutical Discovery and Development — LillyPod, an NVIDIA DGX SuperPOD, significantly accelerates pharmaceutical discovery through massive AI computational power.
• Nvidia: Star Attraction at CES 2026 — Nvidia's Vera Rubin platform integrates co-designed chips and software to build scalable AI factories.
• Here’s how you can secure access to the UK’s most powerful supercomputer — Access to powerful supercomputing is critical for developing advanced AI models and maintaining competitive advantage.
• Is AI Drug Discovery Becoming a Data Infrastructure Race? — AI drug discovery's primary bottleneck is the availability of diverse, relevant biological training data, not model architecture or compute.
• Martin Shkreli on AI, Pharma, and What Actually Matters — Value capture in AI is shifting from intelligence to economics, necessitating fundamental hardware innovation beyond silicon.
• BIO Conference with Kimberly Powell — NVIDIA's Bioneo agent toolkit enables "agentic science" to dramatically accelerate drug discovery and scientific research.

Open in AIssential →

Editorial summary, takeaway, and curation by AIssential. Original article published by The AI in Business Podcast.